Programme overview

Friday, 18th February 2011

Opening Ceremony
6.00 p.m. – 6.15 p.m. Welcome Speech
Dr. Alfredo Polo, Ramon y Cajal University Hospital, Spain

6.15 p.m. – 6.30 p.m. Welcome Speech
Dr. Edgar Löffler, IBt Bebig, Germany

Saturday, 19th February 2011

Introduction to Brachytherapy
8.30 a.m. – 8.50 a.m. New aspects of Brachytherapy
Dr. Alfredo Polo, Ramon y Cajal University Hospital, Spain

8.50 a.m. – 9.10 a.m. Brachytherapy: an effective and well tolerated therapeutic option in the fight against cancer
Dr. Alexander Petrovsky, Cancer Research Center, Russia

Session I: Physics
Chairman: Dr. Sadiqur Rahman Malik, Bangladesh

9.10 a.m. – 9.30 a.m. QA and commissioning of the first Co-60 HDR MultiSource® in Dhaka
Dr. Sadiqur Rahman Malik, Delta Hospital, Bangladesh

9.30 a.m. – 9.50 a.m. Brachytherapy of prostate cancer: first experience with Co-60
Alexey Molokov, Head of the Department of Medical Physics, Regional Clinical Oncology Center, Russia

9.50 a.m. – 10.10 a.m. Brachytherapy with Co-60 vs. Ir-192 – 20 years of Russian experience
Dr. Irina Bocharova, Moscow Research Oncological Institute n.a. Hertsen, Russia

10.10 a.m. – 10.30 a.m. Experiences with HDRplus treatment planning
Mikio Nemoto, Jichi Medical University Hospital, Japan

10.30 a.m. – 11.00 a.m. Coffee Break

11.00 a.m. – 11.50 a.m. HDR Brachytherapy with MultiSource®: Innovation made in Germany
Kentaro Mazur, Antonius Spiller, IBt Bebig, Germany
Session II: Breast
Chairman: Prof. Jean Michel Hannoun-Levi, France

11.50 a.m. – 12.10 p.m.  HDR breast treatment results in Clinique Litoral (Casablanca)
  Prof. Redouane Samlali, Casablanca Clinic, Morocco

12.10 a.m. – 12.30 p.m.  HDR - Brachytherapy for internal mammary lymph nodes in breast cancer patients
  Dr. Alexander Petrovsky, Cancer Research Center, Russia

12.30 p.m. – 1.30 p.m.  Lunch

Session III: Gynaecology
Chairman: Prof. Masanori Nakazawa, Japan

1.30 p.m. – 1.50 p.m.  Radiochemotherapy of cervical cancer with cisplatin
  Prof. Alexandr P. Seryakoe, Treatment and rehabilitation center of Ministry of Public Health and Social Development of the Russian Federation, Russia

1.50 p.m. – 2.10 p.m.  Nursing care for the uterine cancer using the MultiSource® HDR System
  Takako Mori, Jichi Medical University Hospital, Japan

2.10 p.m. – 2.25 p.m.  Co-60 HDR CT based interstitial Brachytherapy using perineal template
  Dr. Koushik Chatterjee, R.G.KAR Medical College Hospital, India

2.25 p.m. – 2.35 p.m.  Co-60 HDR CT based interstitial Brachytherapy for other sites at R.G.KAR Hospital Kolkata India
  Dr. Swapnendu Basu, R.G.KAR Medical College Hospital, India

Session IV: Other applications of Brachytherapy
Chairman: Dr. Frank Kahmann, Germany

3.10 p.m. – 3.30 p.m.  Quality standards for Brachytherapy treatment with seeds
  Dr. Frank Kahmann, Gemeinschaftspraxis Drs. Henkel & Kahmann, LDR, Brachytherapy Trainingscenter at Ullsteinhaus, Germany

3.30 p.m. – 3.50 p.m.  Prostate seed treatment with IsoCord® Seeds
  Dr. Janusz Skowronek, Greater Poland Cancer Centre, Poland

3.50 p.m. – 4.10 p.m.  The role of LDR and HDR Brachytherapy in the management of early and intermediate stage prostate cancer
  Prof. Jean Michel Hannoun-Levi, Centre Antoine Lacassagne, France
Saturday, 20th February 2011

Session V: Reports & Experiences
Chairman: Dr. Jarosław Łyczek, Poland

9.00 a.m. – 9.20 a.m. National Cancer Control program and implementation of cost effective treatment systems for cancer care in India
Dr. Rath, Institute Rotary Cancer Hospital, India

9.20 a.m. – 9.40 a.m. MultiSource® HDR afterloading system: First experiences in Lithuania
Dr. Rasa Dagiene, Klaipeda University Hospital, Lithuania

9.40 a.m. – 10.00 a.m. The paradigm shift from the traditional LDR to HDR-planning and setup: an Indian user viewpoint
Dr. Devesh Gupta, SN Medical College Hospital, India

10.00 a.m. – 10.20 a.m. HDR Brachytherapy practice at the University College Hospital, Ibadan, Nigeria
Dr. A. A. Adenipekun, University College Hospital (UCH), Nigeria

10.20 a.m. – 10.40 a.m. HDR Brachytherapy using Co-60 source for gynaecological cancers: initial experience from UK
Dr. Yoodhvir Nagar, Queen Alexandra Hospital, United Kingdom

Conclusions
10.40 a.m. – 11.30 a.m. Concluding remarks and farewell
Dr. Alfredo Polo, Ramon y Cajal University Hospital, Spain
Dr. Edgar Löffler, IBt Bebig, Germany